According to GlobalData’s medical device pipeline database, 26 Cardiac Resynchronisation Therapy (CRT) devices are in various stages of development globally. GlobalData’s report Cardiac Resynchronisation Therapy (CRT) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 16 are in active development, while the remaining ten are in an inactive stage of development. There are 12 products in the early stages of development, and the remaining four are in the late stages of development.

Cardiovascular Devices are used to detect and treat heart and circulatory system related diseases. Cardiac Resynchronisation Therapy (CRT) is a device used for the treatment of heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Resynchronisation Therapy (CRT) pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Cardiac Resynchronisation Therapy (CRT) devices. Overall, most of these Cardiac Resynchronisation Therapy (CRT) pipeline devices are being developed by private entities.

Key players involved in the active development of Cardiac Resynchronisation Therapy (CRT) include MicroPort Scientific, Biotronik, MicroPort CRM, Biotronik, Boston Scientific, DHS Medical, EBR Systems, IRadimed, Johns Hopkins University and Mayo Clinic.

For a complete picture of the developmental pipeline for Cardiac Resynchronisation Therapy (CRT) devices, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.